Özgür Kırbıyık

Özgür Kırbıyık

Auto-generated profile, based on publicly available information

Özgür Kırbıyık

Department of Medical Genetics , Izmir City Hospital , Izmir , Türkiye

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2019 in Urology Research and Practice
Verified
Journal Article
Closed access
TÖTaha Reşid Özdemir
Taha Reşid Özdemir
BOBerk Ozyilmaz
Berk Ozyilmaz
ÖÇÖzgür Çakmak
Özgür Çakmak
ÖKÖzge Özer Kaya
Özge Özer Kaya
CKCan Köse
Can Köse
MGMerve Saka Güvenç
Merve Saka Güvenç
Objective: The aim of this study was to determine the frequencies of chromosomal abnormalities and Y-chromosome microdeletions in Turkish cases with primary male infertility in a single center. Material and methods: Chromosomal abnormalities and Y-chromosome microdeletions were investigated in 1696 cases with primary male infertility between 2012 and 2017. Karyotype analyzes and Y-chromosome microdeletions analyzes [azoospermia factor (AZF) regions] were performed in all cases by using standard cytogenetic methods and the multiplex polymerase chain reaction method, respectively. Results: Chromosomal abnormalities were found in 142 cases (8.4%; 142/1696). Y-chromosome microdeletions were detected in 46 cases (2.7%; 46/1696). Y-chromosome microdeletions in the AZFc region were found in 20 of 46 cases (43%). Conclusion: This study is one of the few were a large number of cases was studied in Turkey. It indicates that cytogenetic and Y-chromosome microdeletion studies should be conducted in cases with primary male infertility prior to selecting assisted reproductive techniques. Cite this article as: Özdemir TR, Özyılmaz B, Çakmak Ö, Kaya ÖÖ, Köse C, Kırbıyık Ö, et al. Evaluation of chromosomal abnormalities and Y-chromosome microdeletions in 1696 Turkish cases with primary male infertility: A single-center study. Turk J Urol 2020; 46(2): 95-100.

1 April 2021 in International Journal Of Clinical Practice
Verified
Journal Article
Closed access
PDF file
CCCengiz Ceylan
Cengiz Ceylan
BOBerk Ozyilmaz
Berk Ozyilmaz
OKOzgur Kirbiyik
Ozgur Kirbiyik
MUMehmet Can Uğur
Mehmet Can Uğur
OOOzge Ozer
Ozge Ozer
Aims JAK2V617F (JAK2), calreticulin (CALR) and MPL515L/K (MPL) mutations are important in essential thrombocythemia (ET) and may be associated with various clinical consequences of the disease. This study aimed to compare the clinical and haematological parameters of ET patients regarding the mentioned mutations and the role of plateletcrit (PCT). Methods Seventy patients who were diagnosed with ET between 2005 and 2017 in a single centre were included in this descriptive study. The initial symptoms and clinical findings were retrieved from the electronic database. JAK2 gene V617F mutations, MPL gene exon 10 mutations and CALR gene exon 9 DNA sequence analyses were performed. Forty-one healthy volunteers were included to perform ROC curve analysis for interpreting PCT value. Results The distributions of patients according to the mutations were as follows: Thirty-seven (52.9%) patients were JAK2-positive, 15 (21.4%) were CALR-positive, 2 (2.8%) patients were positive for both CALR and JAK2, and 1 (1.4%) was only MPL-positive. Fifteen (21.4%) patients were triple-negative. The ET patients with JAK2 mutation showed a higher level of haemoglobin at the time of diagnosis. The ET patients with CALR mutation presented with higher platelet and LDH levels (P = .002 and P = .001, respectively). The PCT level was higher in the CALR-positive group when compared to the others (P = .026). A sensitivity value of 97.6% and specificity value of 98.6% were determined regarding PCT% at a cut-off value of 0.37 in ET patients. In CALR-positive patients, the sensitivity and specificity values were 100% for the PCT at a cut-off value of 0.42%. Conclusion We determined that the platelet count and blood LDH level was high in the ET patient group with CALR mutation. Besides, we found that the blood haemoglobin level was higher in the ET patient group with JAK2 mutation. Additionally, the PCT level was higher in the CALR group when compared to the other patient groups.

24 February 2025 in The Egyptian Journal of Bronchology
Verified
Journal Article
Open access
PDF file
DUDamla Serçe Unat
Damla Serçe Unat
ŞAŞener Arikan
Şener Arikan
ÖKÖzgür Kirbiyik
Özgür Kirbiyik
GBGünseli Balci
Günseli Balci
SESinem Ermin
Sinem Ermin
AMAydan Mertoğlu
Aydan Mertoğlu
Introduction: Brain metastasis (BM) in non-small cell lung cancer (NSCLC) is still an important reason for morbidity and mortality despite the advances in cancer treatment. Using tyrosine kinase inhibitors against epidermal growth factor receptors (EGFR) mutations revolutionized NSCLC treatment. We investigated whether the presence of EGFR mutation influences survival in patients with lung adenocarcinoma with BM. Material and methods: The data of the patients with pathological diagnoses of NSCLC and BM at tertiary hospitals were analyzed retrospectively in terms of survival. A total of 2554 patients diagnosed with NSCLC pathologically between 01 January 2010 and 01 January 2021 were identified. After the exclusion of patients with a lack of data, unknown EGFR mutation status, no brain metastasis, and additional malignancy 336 patients were included in the study. Results: It was found that EGFR ( +) patients were more female dominant (48.6% vs 13.3% p < 0.0001) and were have less history of smoking (47.2% vs 87.1%, p < 0.0001) and were better survival (79.2% vs 92.8%). We found negativity of EGFR increased death risk by 1.700 times (95% CI 1.323–2.183, p < 0.0001) in univariate analysis and by 1.724 times (95% CI 1.251–2.377, p = 0.0001) in multivariate analysis. When overall survivals were compared estimated overall survival time of EGFR ( −) patients was 10.088 (95% CI 8.571–11.606) months and of EGFR ( +) patients was 11.829 months (95% CI 10.336–13.323) (p < 0.001). Conclusion: EGFR positivity was associated with survival. Also, survival was significantly longer in EGFR-positive patients with brain metastases diagnosed with NSCLC.

1 October 2019 in Turkish Archives of Otorhinolaryngology
Verified
Journal Article
Open access
BOBerk Ozyilmaz
Berk Ozyilmaz
GMGul Caner Mercan
Gul Caner Mercan
OKOzgur Kirbiyik
Ozgur Kirbiyik
TÖTaha Reşid Özdemir
Taha Reşid Özdemir
SOSamira Ozkara
Samira Ozkara
AKAltug Koc
Altug Koc
Objective: The aim of this study is to investigate the efficiency of a first-line molecular genetic evaluation approach, in children with deafness. Methods: Patients who were found to have sensorineural hearing loss by age-appropriate audiological tests were selected for the molecular genetic evaluation. The molecular genetic evaluation was carried out with GJB2 gene sequence analysis and mtDNA m.1555A> G mutation Restriction Fragment Length Polymorphism (RFLP) analysis. Additionally, in a small group of patients, hearing loss Multiplex Ligation-dependent Probe Amplification (MLPA) analysis was done out to identify the possible role of copy number changes. Results: In this Turkish cohort, which included 104 index patients and 78 relatives, 33 (31.7%) had Pathogenic/Likely Pathogenic variants. One or more GJB2 sequence variants were identified in 46 (44.1%) of the 104 index patients. The homozygous c.35delG mutation by itself explained the etiology in 24% of our ARSNHL group. In one (5%) of the 20 patients of MLPA group, a hemizygous deletion in POU3F4 gene was detected. Conclusion: In our Turkish cohort, we applied a first-line molecular genetic evaluation approach using G . GJB2 gene sequence analysis and mtDNA in .1555A> G RFLP analysis. This approach revealed the genetic etiology of 44.1% of our index patients. Additionaly, the results of hearing loss MLPA analysis revealed the limited role of copy number changes in this patient group. Furthermore, with a detailed genotype-phenotype association workup, 2 rare cases of Deafness with Palmoplantar Hyperkeratosis and Keratitis-lchthyosis-Deafness syndrome were reported.

1 February 2021 in The Clinical Respiratory Journal
Verified
Journal Article
Closed access
PDF file
SESinem Ermin
Sinem Ermin
ÖBözgür Batum
özgür Batum
MGMerve Saka Güvenç
Merve Saka Güvenç
Gülden DinizGülden Diniz
Gülden Diniz
AAAYSU AYRANCI
AYSU AYRANCI
UYUfuk Yılmaz
Ufuk Yılmaz

26 December 2023 in Clinical Endocrinology
Verified
Journal Article
Closed access
GKGözde Akın Kağızmanlı
Gözde Akın Kağızmanlı
ÖKÖzgür Kırbıyık
Özgür Kırbıyık
AAAyhan Abacı
Ayhan Abacı
EBEce Böber
Ece Böber
UYUluç Yiş
Uluç Yiş
KDKorcan Demir
Korcan Demir